These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
168 related articles for article (PubMed ID: 17522561)
21. Tolerability of combined treatment with lithium and paroxetine in patients with bipolar disorder and depression. Fagiolini A; Buysse DJ; Frank E; Houck PR; Luther JF; Kupfer DJ J Clin Psychopharmacol; 2001 Oct; 21(5):474-8. PubMed ID: 11593071 [TBL] [Abstract][Full Text] [Related]
22. Analyses of treatment-emergent mania with olanzapine/fluoxetine combination in the treatment of bipolar depression. Keck PE; Corya SA; Altshuler LL; Ketter TA; McElroy SL; Case M; Briggs SD; Tohen M J Clin Psychiatry; 2005 May; 66(5):611-6. PubMed ID: 15889948 [TBL] [Abstract][Full Text] [Related]
23. Pharmacotherapy for social anxiety disorder: an update. Van Ameringen M; Mancini C; Patterson B; Simpson W Isr J Psychiatry Relat Sci; 2009; 46(1):53-61. PubMed ID: 19728573 [TBL] [Abstract][Full Text] [Related]
24. The treatment of SSRI-resistant depression in adolescents (TORDIA): in search of the best next step. Brent DA Depress Anxiety; 2009; 26(10):871-4. PubMed ID: 19798756 [No Abstract] [Full Text] [Related]
25. Focus on paroxetine. Green B Curr Med Res Opin; 2003; 19(1):13-21. PubMed ID: 12661775 [TBL] [Abstract][Full Text] [Related]
26. [Bipolar depression: a review of current therapeutic strategies]. Thuile J; Even C; Guelfi JD Encephale; 2006 Oct; 32(5 Pt 1):767-74. PubMed ID: 17099601 [TBL] [Abstract][Full Text] [Related]
27. The role of drug therapy in social phobia. Lydiard RB J Affect Disord; 1998 Sep; 50 Suppl 1():S35-9. PubMed ID: 9851577 [TBL] [Abstract][Full Text] [Related]
29. Paroxetine discontinuation syndrome in association with sertindole therapy. Walker-Kinnear M; McNaughton S Br J Psychiatry; 1997 Apr; 170():389. PubMed ID: 9246265 [No Abstract] [Full Text] [Related]
30. More cases of paroxetine withdrawal syndrome. Pacheco L; Malo P; Aragues E; Etxebeste M Br J Psychiatry; 1996 Sep; 169(3):384. PubMed ID: 8879736 [No Abstract] [Full Text] [Related]
31. Mania from dose-related ziprasidone augmentation of an SSRI. Privitera MR; Maharaj K J Clin Psychiatry; 2003 Nov; 64(11):1393-4. PubMed ID: 14658958 [No Abstract] [Full Text] [Related]
32. [Selective serotonin reuptake inhibitors in treatment of compulsive symptoms within the scope of schizophrenia]. Scholl HP; Kasper S; Danos P; Höflich G; Möller HJ Nervenarzt; 1994 Jul; 65(7):478-81. PubMed ID: 7800092 [TBL] [Abstract][Full Text] [Related]
33. [Psychopharmaceuticals for treatment of suicidal patients and for suicide prevention]. Haußmann R; Bauer M; Lewitzka U; Müller-Oerlinghausen B Nervenarzt; 2016 May; 87(5):483-7. PubMed ID: 26952239 [TBL] [Abstract][Full Text] [Related]
34. Novel psychotropic medications in children: new toxicities to master. Jacobs ES; Dickstein DP; Liebelt EL Pediatr Emerg Care; 2001 Jun; 17(3):226-31. PubMed ID: 11437154 [No Abstract] [Full Text] [Related]
38. Effect of paroxetine on seizure length during electroconvulsive therapy. Curran S Acta Psychiatr Scand; 1995 Sep; 92(3):239-40. PubMed ID: 7484206 [TBL] [Abstract][Full Text] [Related]
39. Psychiatric illness and the serotonin syndrome: an emerging adverse drug effect leading to intensive care unit admission. Nijhawan PK; Katz G; Winter S Crit Care Med; 1996 Jun; 24(6):1086-9. PubMed ID: 8681579 [No Abstract] [Full Text] [Related]
40. Recognition and treatment of serotonin syndrome. Frank C Can Fam Physician; 2008 Jul; 54(7):988-92. PubMed ID: 18625822 [No Abstract] [Full Text] [Related] [Previous] [Next] [New Search]